

Synthesis of Thiazolidine-2-thione Derivatives and Evaluation of Their Hepatoprotective Effects

Koji YONEDA,* Atsutoshi OTA and Yoichi KAWASHIMA

Central Research Laboratories, Santen Pharmaceutical Co., Ltd., 9-19, Shimoshinjo 3-chome, Higashiyodogawa-ku, Osaka 533, Japan. Received August 3, 1992

A series of *N*-(mercaptoalkyl)thiazolidine-2-thiones and their derivatives were synthesized and evaluated for hepatoprotective activities against *Propionibacterium acnes*-lipopolysaccharide (*P. acnes*-LPS)-induced liver injury in mice and *in vitro* lipid peroxide (LPO) formation in rat liver microsomes. Reaction of *N*-(*p*-methoxybenzylthioalkyl)cysteine methyl ester (11) with 1,1'-thiocarbonyldiimidazole followed by deprotection gave the corresponding thiazolidine-2-thione derivatives. Among the compounds synthesized, 1a and 2a showed the most potent hepatoprotective activities against *P. acnes*-LPS-induced liver injury. Compounds 1a–f and 4 inhibited LPO formation *in vitro*. Compounds 1a and 2a were chosen for further pharmacological evaluations.

Keywords thiazolidine-2-thione; radical scavenger; liver injury; *P. acnes*-LPS; lipid peroxide

In the course of our recent studies on the development of hepatoprotective agents, we found a novel cyclic disulfide, SA3443,¹⁾ which showed a potent protective effect against immunologically induced liver injury in an *in vivo* model. In addition to immunological dysfunctions, lipid peroxidation is thought to be one of the causes of liver injury.²⁾ Therefore, for the purpose of developing a new hepatoprotective agent, we have designed compounds which possess dual actions, namely inhibitory actions on both immunologically induced liver injury and lipid peroxide (LPO) formation.

Initially, we designed *N*-(mercaptoacyl)thiazolidine-2-thione (A) (Chart 1). Compound A could be unstable, because the *N*-acyl bond of *N*-acylthiazolidine-2-thione is easily cleaved in the presence of base or nucleophile.³⁾ Accordingly, we designed a series of *N*-(mercaptoalkyl)thiazolidine-2-thiones (1a–f). We incorporated in the chemical structures of these compounds a partial structure

of bucillamine,⁴⁾ an immunomodulator developed in our laboratories, in the expectation that the products would have immunological effects. In addition, the thioamide moiety, which could have an oxygen radical-scavenging action,⁵⁾ was included in the bucillamine structure. We also designed 2a, 2d and 2e which have a thioester group constructed from ester and mercapto groups in 1a, 1d and 1e. To examine the roles of the thiazolidine-2-thione structure and the functional groups of the thiazolidine-2-thione ring, analogues (3 and 4) were designed. In this paper, we describe the preparation of *N*-(mercaptoalkyl)thiazolidine-2-thione derivatives. The effects of these compounds on immunologically induced liver injury and on LPO formation are also discussed.

Chemistry The *N*-(mercaptoalkyl)thiazolidine-2-thiones and their derivatives were prepared by the following methods. Aldehydes (10a–d) were prepared by protection of SH groups of 5a–d with *p*-methoxybenzyl chloride (MPMCl),⁶⁾ followed by a reduction to alcohol using lithium aluminum hydride (LiAlH₄) and Swern oxidation.⁷⁾ Aldehyde 10e was prepared by introduction of an S group at the acetal (7) with *p*-methoxybenzylmercaptan (MPMSH), followed by deprotection of the diethyl acetal. Aldehyde 10f was prepared by Michael-type addition of MPMSH to the α,β -unsaturated aldehyde (9) by the use of a catalytic amount of 4-dimethylaminopyridine (DMAP) (Chart 2).

N-Alkylcysteines (11a–f) were prepared by reductive amination⁸⁾ of the aldehydes (10a–f) with cystine dimethylester dihydrochloride in MeOH using NaBH₃CN in the presence of Molecular sieves (M.S.) 3A, followed by S–S cleavage using (*n*-Bu)₃P.⁹⁾ Reaction of 11a–f with 1,1'-thiocarbonyldiimidazole in CHCl₃ gave the ring closed products (12a–f). The diastereoisomers (12b and 12c) could be separated by column chromatography. The deblocking of the *p*-methoxybenzyl (MPM) group was carried out in trifluoroacetic acid (TFA) using trifluoromethanesulfonic acid (TFMSA) in the presence of thioanisole.¹⁰⁾ The conditions of run 1 (Table I) gave two products (1a and 2a), which could easily be separated by column chromatography. Depending on the deprotection conditions, 1a or 2a was obtained selectively (runs 2 and 3).









Chart 1



a: MPMCl, NaOH / EtOH - H₂O b: LiAlH₄ / THF - Et₂O c: Swern oxidation
d: MPMSH, NaOH / EtOH - H₂O e: HCl / acetone - H₂O f: MPMSH, 4-DMAP / MeOH

Chart 2



a: cystine dimethyl ester dihydrochloride, NaBH₃CN, M.S. 3A / MeOH
b: (n-Bu)₃P / EtOH - H₂O c: 1, 1'-thiocarbonyldiimidazole / CHCl₃
d: CF₃SO₃H, thioanisole / CF₃CO₂H e: 1, 1'-carbonyldiimidazole / DMF
f: LiAlH₄ / THF - Et₂O

Chart 3

A thiazolidin-2-one derivative (**3**) was synthesized by ring construction with an *N*-alkylcysteine (**11a**) and 1,1'-carbonyldiimidazole in *N,N*-dimethylformamide (DMF), followed by deprotection under the same reaction conditions as used in run 3.

A 4-hydroxymethyl derivative (**4**) was synthesized by LiAlH₄ reduction of the methyl ester in **12a**, followed by deprotection under the same reaction conditions as used in run 2.

TABLE I. Deprotection of *S-p*-Methoxybenzyl (S-MPM) Group

Run	Temp. (°C)	Time (min)	CF ₃ SO ₃ H (eq)	C ₆ H ₅ SMc (eq)	1a (%)	2a (%)
1	25	15	2	2	49	13
2	0	15	2	2	62	0
3	25	30	4	4	3	60

TABLE II. Effects of Thiazolidine-2-thione Derivatives on the Mortality of Mice with Acute Hepatic Failure Induced by *P. acnes*-LPS

Compd. No.	Mortality (No. dead/total)	
	0-48 h	
Control	4/6	67%
1a	0/5	0%
1b	5/6	83%
1c	4/6	67%
1d	2/6	33%
1e	3/6	50%
1f	4/5	80%
2a	0/6	0%
2d	4/6	67%
2e	3/6	50%
3	2/5	40%
4	4/5	80%

Biological Results and Discussion

The compounds synthesized above were initially examined for hepatoprotective activities against *Propionibacterium acnes*-lipopolysaccharide (*P. acnes*-LPS)-induced liver injury in mice.¹¹⁾ The results are summarized in Table II. Compound **1a** and the bicyclic compound **2a** showed remarkable hepatoprotective activity. On the other hand, the activities of **1b-f**, **2d** and **2e** were rather weak. These results clearly indicate that the substitution pattern and the N-SH length of the *N*-alkyl chain in **1a-f** profoundly influenced the hepatoprotective activity. In the bicyclic compounds **2a**, **2d** and **2e**, the substitution pattern and the size of the thiolactone ring profoundly influenced the activity. Furthermore, the thiazolidin-2-one derivative (**3**) and the derivative (**4**) having a hydroxymethyl group

TABLE III. Effects of Thiazolidine-2-thione Derivatives on the Formation of Lipid Peroxide by ADP-Fe²⁺-Ascorbic Acid in Rat Liver Microsomes (*in Vitro*)

Compd. No.	Inhibition of LPO formation (%)		
	Conc. (M)	10 ⁻³	10 ⁻⁴
1a		97.0	11.2
1b		97.8	11.1
1c		82.2	10.5
1e		95.3	14.7
2a		29.6	17.5
2d		15.9	NT
3		9.4	NT
4		95.2	19.5
Bucillamine		16.1	NT

NT, represents not-tested.

instead of the methoxycarbonyl group did not show the activity. These results suggest that the 2-thioxo group of the thiazolidine moiety and the ester group on the thiazolidine-2-thione ring considerably influence the hepatoprotective activity.

We next examined the inhibitory action on LPO formation by ADP-Fe²⁺-ascorbic acid in rat liver microsomes. The results are shown in Table III. While compounds **1a**–**e** and **4** having an SH group in the *N*-alkyl chain showed an inhibitory action on the formation of LPO, bicyclic compounds in which the SH group is protected by a thioester construction did not show the activity in spite of the presence of the thiazolidine-2-thione ring. On the other hand, the parent compound, bucillamine, and the 2-one compound (**3**) did not show inhibitory action on the formation of LPO. From these results, we can conclude that the existence of both the thiazolidine-2-thione ring and the SH group in the molecule is necessary for inhibitory activity on LPO formation *in vitro*.

As a result, **1a** was found to inhibit both immunologically induced liver injury and LPO formation. Although compound **2a** did not show inhibitory activity on LPO formation *in vitro*, it might act as an equivalent of **1a** by being metabolized *in vivo*.

Consequently, compounds **1a** and **2a** were selected as candidates for further pharmacological evaluations. These studies are in progress.

Experimental

Melting points were determined in open glass capillaries with a Yamato MP-21 or Büchi 535 melting point apparatus and are uncorrected. Elemental analyses were performed by a Yanagimoto MT-3 CHN Corder elemental analyzer. IR spectra were recorded on a JASCO A-302 or Perkin Elmer 1600 series FTIR infrared spectrophotometer. High resolution mass spectra (HRMS) were obtained on a Hitachi M-80B spectrometer in the EI mode with samples introduced directly into the ion source for spectral determination. NMR spectra were measured by a JEOL GX-400 spectrometer using tetramethylsilane as an internal standard. Chemical shifts are given in ppm and coupling constants are given in hertz. The following abbreviations are used: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, br=broad, dq=doublet of quartets, dd=doublet of doublets and ddd=doublet of doublets of doublets. Fuji-Davison Silica gel BW-300 (200–325 mesh) was used for column chromatography. Rotations at the sodium D line were determined at 25 °C with a JASCO DIP-140 digital polarimeter (1-dm cells). Analytical thin layer chromatography (TLC) was performed using pre-coated glass-backed plates (Merck Kieselgel 60 F₂₅₄) and bands were visualized under ultraviolet light.

2-(4-Methoxybenzylthio)-2-methylpropanal (**10a**) (General Procedure)

A 2 N NaOH solution (597 ml, 1.19 mol) and MPMCl (86.9 ml, 0.64 mol) were added to a solution of 2-mercapto-2-methylpropanoic acid (**5a**) (70.0 g, 0.58 mol) in EtOH (600 ml) under ice cooling. The reaction mixture was stirred at room temperature overnight and then concentrated *in vacuo* followed by acidification with 6 N HCl. The mixture was extracted with AcOEt. The organic layer was washed with H₂O and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residue was collected by filtration and washed with iso-Pr₂O to give **6a** (97.0 g, 69%), mp 92–93 °C (*n*-hexane–AcOEt). IR (KBr): 1685, 1610, 1515, 1302, 1294, 1254, 1173, 1035 cm⁻¹. ¹H-NMR (CDCl₃) δ: 1.57 (6H, s, C₂-CH₃), 3.78 (3H, s, OCH₃), 3.86 (2H, s, SCH₂Ar), 6.82 (2H, d, *J*=8.8, aromatic protons), 7.24 (2H, d, *J*=8.8, aromatic protons). A solution of **6a** (80.0 g, 0.33 mol) in anhydrous tetrahydrofuran (THF) (50 ml) was added to a stirred suspension of LiAlH₄ (13.64 g, 0.34 mol) in anhydrous ether (350 ml) at room temperature. Stirring was continued at the same temperature overnight, then the reaction mixture was decomposed with AcOEt, H₂O and 6 N HCl, and the mixture was extracted with AcOEt. The organic layer was washed with 1 N HCl, H₂O and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The crude product was oxidized using the Swern oxidation procedure.⁷⁾ A solution of the crude alcohol was added to a cold (–60 °C) stirred solution of (COCl)₂ (32.8 ml, 0.38 mol) and dimethyl sulfoxide (DMSO) (53.4 ml, 0.75 mol) in dry CH₂Cl₂ (730 ml). The solution was stirred for 10 min at –60 °C, and then Et₃N (238 ml, 1.71 mol) was added. The mixture was stirred at 20 °C for a period of 1.5 h, then the reaction was quenched with H₂O and the whole was extracted with CH₂Cl₂. The organic layer was washed with H₂O and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residue was chromatographed on silica gel to give **10a** (62.6 g, 83%) as a colorless oil.

2-(4-Methoxybenzylthio)-2-methylpropanal (**10a**): (57% overall yield). IR (neat): 2964, 2928, 1707, 1611, 1514, 1462, 1302, 1247, 1176, 1126, 1034 cm⁻¹. ¹H-NMR (CDCl₃) δ: 1.38 (6H, s, C₂-CH₃ × 2), 3.47 (2H, s, SCH₂Ar), 3.78 (3H, s, OCH₃), 6.82 (2H, d, *J*=8.8, aromatic protons), 7.18 (2H, d, *J*=8.8, aromatic protons), 9.12 (1H, s, C₁-H). HRMS *m/z* (M⁺): Calcd for C₁₂H₁₆O₂S: 224.0870. Found: 224.0900.

(±)-2-(4-Methoxybenzylthio)propanal (**10bc**): Compound **10bc** was prepared starting from **5bc** (enantiomeric mixture) by the same procedures as described for the synthesis of compound **10a** (37% overall yield). Colorless oil. IR (neat): 1710, 1611, 1514, 1245, 1032 cm⁻¹. ¹H-NMR (CDCl₃) δ: 1.33 (3H, d, *J*=6.8, C₂-CH₃), 3.13 (1H, dq, *J*=4.4, 6.8, C₂-H), 3.52 (1H, d, *J*=13.2, SCHAr), 3.60 (1H, d, *J*=13.2, SCHAr), 3.80 (3H, s, OCH₃), 6.85 (2H, d, *J*=8.8, aromatic protons), 7.23 (2H, d, *J*=8.8, aromatic protons), 9.20 (1H, d, *J*=4.4, C₁-H). HRMS *m/z* (M⁺): Calcd for C₁₁H₁₄O₂S: 210.0714. Found: 210.0710.

3-(4-Methoxybenzylthio)-2,2-dimethylpropanal (**10d**): Compound **10d** was prepared starting from **5d** by the same procedures as described for the synthesis of compound **10a** (23% overall yield). Colorless oil. IR (neat): 2928, 1723, 1681, 1609, 1510, 1460, 1245, 1174, 1032 cm⁻¹. ¹H-NMR (CDCl₃) δ: 1.11 (6H, s, C₂-CH₃ × 2), 2.57 (2H, s, C₃-H₂), 3.67 (2H, s, SCH₂Ar), 3.80 (3H, s, OCH₃), 6.85 (2H, d, *J*=8.3, aromatic protons), 7.22 (2H, d, *J*=8.3, aromatic protons), 9.41 (1H, s, C₁-H). HRMS *m/z* (M⁺): Calcd for C₁₃H₁₈O₂S: 238.1027. Found: 238.1023.

2-(4-Methoxybenzylthio)acetaldehyde (**10e**) A 1 N NaOH solution (29 ml, 29 mmol) and 97% bromoacetaldehyde diethyl acetal (**7**) (2.06 ml, 13.3 mmol) were added dropwise to a solution of 90% MPMSH (2.06 ml, 13.3 mmol) in EtOH (30 ml) under ice cooling. The reaction mixture was stirred at room temperature overnight, concentrated *in vacuo*, and extracted with Et₂O. The organic layer was washed with H₂O and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residue was chromatographed on silica gel to give **8** (1.74 g, 49%) as a colorless oil. IR (neat): 2980, 2928, 1611, 1513, 1465, 1301, 1246, 1175, 1122, 1053 cm⁻¹. ¹H-NMR (CDCl₃) δ: 1.22 (6H, t, CH₃CH₂O × 2), 2.58 (2H, d, *J*=5.4, MPMSCH₂), 3.59 (4H, m, OCH₂ × 2), 3.75 (2H, s, SCH₂Ar), 3.80 (3H, s, OCH₃), 4.55 (1H, t, *J*=5.4, CH(OEt)₂), 6.84 (2H, d, *J*=8.8, aromatic protons), 7.25 (2H, d, *J*=8.8, aromatic protons). A solution of **8** (1.14 g, 4.22 mmol) in acetone (10 ml) and 1 N HCl (1 ml) was stirred at room temperature overnight. The reaction mixture was extracted with AcOEt. The organic layer was washed with H₂O and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residue was chromatographed on silica gel to give **10e** (0.58 g, 70%) as a colorless oil. IR (neat): 3000, 2836, 1717, 1611, 1514, 1465, 1303, 1244, 1176, 1033 cm⁻¹. ¹H-NMR (CDCl₃) δ: 3.08 (2H, d, *J*=3.4, C₂-H₂), 3.59 (2H, s, SCH₂Ar), 3.80 (3H, s, OCH₃), 6.86 (2H, d, *J*=8.8, aromatic protons), 7.22 (2H, d, *J*=8.8, aromatic protons), 9.41 (1H, t, *J*=3.4, C₁-H).

HRMS m/z (M^+): Calcd for $C_{10}H_{12}O_2S$: 196.0557. Found: 196.0558.

3-(4-Methoxybenzylthio)-3-methylbutanal (10f) A mixture of 97% 3-methyl-2-butenal (**9**) (7.71 ml, 77.5 mmol) and 90% MPMSH (8.00 ml, 51.7 mmol) in MeOH (10 ml) containing a catalytic amount of DMAP was stirred at room temperature overnight. The reaction mixture was concentrated *in vacuo*, and the residue was chromatographed on silica gel to give **10f** (12.01 g, 98%) as a colorless oil. IR (neat): 2960, 2928, 1717, 1611, 1513, 1301, 1249, 1176, 1132, 1033 cm^{-1} . 1H -NMR ($CDCl_3$) δ : 1.46 (6H, s, C_3 -CH₃ $\times$ 2), 2.55 (2H, d, J =2.9, C_2 -H₂), 3.74 (2H, s, SCH₂Ar), 3.78 (3H, s, OCH₃), 6.83 (2H, d, J =8.8, aromatic protons), 7.24 (2H, d, J =8.8, aromatic protons), 9.83 (1H, t, J =2.9, C_1 -H). HRMS m/z (M^+): Calcd for $C_{13}H_{18}O_2S$: 238.1027. Found: 238.1029.

N-[2-(4-Methoxybenzylthio)-2-methylpropyl]-L-cysteine Methyl Ester (11a) (General Procedure) L-Cysteine dimethyl ester dihydrochloride (4.53 g, 13.3 mmol) and M.S. 3A (3 g) were added to a stirred solution of the aldehyde **10a** (5.95 g, 26.5 mmol) in MeOH (140 ml) at room temperature. The mixture was stirred at the same temperature for 30 min, then 95% NaBH₄CN (1.75 g, 26.5 mmol) was added and the whole was stirred at room temperature overnight. The reaction was quenched by careful addition of saturated NaHCO₃ solution, and the mixture was extracted with AcOEt. The organic layer was washed with H₂O and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. (*n*-Bu)₃P (6.61 ml) was added to a solution of the residue in MeOH (170 ml) and H₂O (20 ml) at room temperature. The reaction mixture was stirred at the same temperature for 2 h, concentrated *in vacuo* and extracted with AcOEt. The organic layer was washed with brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residue was chromatographed on silica gel to give **11a** (4.96 g, 54%) as a pale yellow oil.

N-[2-(4-Methoxybenzylthio)-2-methylpropyl]-L-cysteine Methyl Ester (11a): IR (neat): 2956, 1736, 1611, 1514, 1249, 1175, 1033 cm^{-1} . 1H -NMR ($CDCl_3$) δ : 1.32 (3H, s, C_2 -CH₃), 1.34 (3H, s, C_2 -CH₃), 2.38 (1H, d, J =11.7, C_1 -H), 2.72 (1H, d, J =11.7, C_1 -H), 2.78 (2H, t-like, J =5.9, C_3 -H₂), 3.38 (1H, t, J =5.9, C_2 -H), 3.66 (1H, d, J =12.0, SCHAr), 3.71 (1H, d, J =12.0, SCHAr), 3.76 (3H, s, ArOCH₃ or CO₂CH₃), 3.78 (3H, s, CO₂CH₃ or ArOCH₃), 6.83 (2H, d, J =8.8, aromatic protons), 7.27 (2H, d, J =8.8, aromatic protons). $[\alpha]_D^{25}$ -14.6° (c =1.0, CHCl₃). HRMS m/z (M^+): Calcd for $C_{16}H_{23}NO_3S_2$: 343.1274. Found: 343.1285.

N-[2-(4-Methoxybenzylthio)propyl]-L-cysteine Methyl Ester (11bc) (inseparable diastereomixture): Compound **11bc** was prepared starting from **10bc** by the same procedures as described for the synthesis of compound **11a** (66% overall yield). Pale yellow oil. IR (neat): 2952, 1736, 1611, 1513, 1463, 1302, 1247, 1174, 1033 cm^{-1} . HRMS m/z (M^+): Calcd for $C_{15}H_{23}NO_3S_2$: 329.1118. Found: 329.1086.

N-[3-(4-Methoxybenzylthio)-2,2-dimethylpropyl]-L-cysteine Methyl Ester (11d): Compound **11d** was prepared starting from **10d** by the same procedures as described for the synthesis of compound **11a** (53% overall yield). Pale yellow oil. IR (neat): 2948, 1736, 1609, 1511, 1463, 1432, 1299, 1247, 1194, 1173, 1031 cm^{-1} . 1H -NMR ($CDCl_3$) δ : 0.93 (3H, s, C_2 -CH₃), 0.94 (3H, s, C_2 -CH₃), 2.25 (1H, d, J =11.7, C_1 -H), 2.41 (1H, d, J =12.2, C_3 -H), 2.50 (1H, d, J =12.2, C_3 -H), 2.52 (1H, d, J =11.7, C_1 -H), 2.73 (2H, brs, C_3 -H₂), 3.35 (1H, t, J =5.4, C_2 -H), 3.66 (2H, s, SCH₂Ar), 3.75 (3H, s, ArOCH₃ or CO₂CH₃), 3.80 (3H, s, CO₂CH₃ or ArOCH₃), 6.84 (2H, d, J =8.3, aromatic protons), 7.23 (2H, d, J =8.3, aromatic protons). $[\alpha]_D^{25}$ -13.8° (c =1.0, CHCl₃). HRMS m/z (M^+): Calcd for $C_{17}H_{27}NO_3S_2$: 357.1431. Found: 357.1425.

N-[2-(4-Methoxybenzylthio)ethyl]-L-cysteine Methyl Ester (11e): Compound **11e** was prepared starting from **10e** by the same procedures as described for the synthesis of compound **11a** (23% overall yield). Pale yellow oil. IR (neat): 2951, 2835, 1735, 1610, 1584, 1512, 1464, 1302, 1248, 1175, 1034 cm^{-1} . 1H -NMR ($CDCl_3$) δ : 2.50—2.85 (6H, m, C_3 -H₂, C_1 -H₂, C_2 -H₂), 3.43 (1H, t, J =5.9, C_2 -H), 3.75 (2H, m, SCH₂Ar), 3.76 (3H, s, ArOCH₃ or CO₂CH₃), 3.80 (3H, s, CO₂CH₃ or ArOCH₃), 6.84 (2H, d, J =8.3, aromatic protons), 7.23 (2H, d, J =8.3, aromatic protons). $[\alpha]_D^{25}$ -33.8° (c =1.0, CHCl₃). HRMS m/z (M^+): Calcd for $C_{14}H_{21}NO_3S_2$: 315.0962. Found: 315.0962.

N-[3-(4-Methoxybenzylthio)-3-methylbutyl]-L-cysteine Methyl Ester (11f): Compound **11f** was prepared starting from **10f** by the same procedures as described for the synthesis of compound **11a** (57% overall yield). Pale yellow oil. IR (neat): 2952, 2924, 1736, 1611, 1513, 1464, 1301, 1248, 1174, 1033 cm^{-1} . 1H -NMR ($CDCl_3$) δ : 1.32 (6H, s, C_3 -CH₃ $\times$ 2), 3.43 (1H, t, J =5.4, C_2 -H), 3.68 (2H, s, SCH₂Ar), 3.76 (3H, s, ArOCH₃ or CO₂CH₃), 3.78 (3H, s, CO₂CH₃ or ArOCH₃), 6.83 (2H, d, J =8.8, aromatic protons), 7.25 (2H, d, J =8.8, aromatic protons). $[\alpha]_D^{25}$ -12.1° (c =1.0, CHCl₃). HRMS m/z (M^+): Calcd for $C_{17}H_{27}NO_3S_2$: 357.1431. Found: 357.1398.

Methyl (4R)-3-[2-(4-Methoxybenzylthio)-2-methylpropyl]-2-thioxothiazolidine-4-carboxylate (12a) (General Procedure) 1,1'-Thiocarbonyldiimidazole (90%, 3.03 g, 15.3 mmol) was added to a solution of **11a** (5.00 g, 14.6 mmol) in CHCl₃ (90 ml) at room temperature. The reaction mixture was stirred at the same temperature for 1 h, washed with 3N HCl, H₂O and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residue was collected by filtration and washed with iso-Pr₂O. Recrystallization from AcOEt gave **12a** (5.10 g, 91%) as colorless needles.

Methyl (4R)-3-[2-(4-Methoxybenzylthio)-2-methylpropyl]-2-thioxothiazolidine-4-carboxylate (12a): mp 125—127°C. IR (KBr): 2964, 1743, 1609, 1514, 1443, 1408, 1303, 1242, 1217, 1177, 1130, 1032 cm^{-1} . 1H -NMR ($CDCl_3$) δ : 1.35 (3H, s, C_2 -CH₃), 1.48 (3H, s, C_2 -CH₃), 3.23 (1H, d, J =15.1, C_1 -H), 3.37 (1H, d, J =11.7, C_5 -H), 3.64 (1H, dd, J =7.8, 11.7, C_3 -H), 3.70 (1H, d, J =12.7, SCHAr), 3.77 (1H, d, J =12.7, SCHAr), 3.79 (6H, s, ArOCH₃, CO₂CH₃), 4.81 (1H, d, J =15.1, C_1 -H), 5.70 (1H, d, J =7.8, C_4 -H), 6.84 (2H, d, J =8.8, aromatic protons), 7.21 (2H, d, J =8.8, aromatic protons). $[\alpha]_D^{25}$ -63.7° (c =1.0, CHCl₃). Anal. Calcd for $C_{17}H_{23}NO_3S_3$: C, 52.96; H, 6.01; N, 3.63. Found: C, 52.89; H, 5.84; N, 3.55.

Methyl (4R)-3-[2-(4-Methoxybenzylthio)propyl]-2-thioxothiazolidine-4-carboxylate (12b and 12c): Compounds **12b** and **12c** were prepared starting from a mixture of **11bc** by the same procedures as described for the synthesis of compound **12a**. Diastereomeric compounds **12b** and **12c** were easily separated by column chromatography. **12b**: (41% yield). Colorless needles, mp 60—62°C (*n*-hexane-AcOEt). TLC R_f 0.40, *n*-hexane-AcOEt 2:1. IR (KBr): 2972, 1731, 1610, 1514, 1406, 1287, 1253, 1210, 1173, 1115, 1032 cm^{-1} . 1H -NMR ($CDCl_3$) δ : 1.31 (3H, d, J =6.8, C_2 -CH₃), 3.02 (1H, dd, J =10.3, 14.2, C_1 -H), 3.29 (1H, m, C_2 -H), 3.36 (1H, dd, J =1.5, 11.7, C_5 -H), 3.54 (1H, dd, J =8.8, 11.7, C_5 -H), 3.66 (1H, d, J =13.2, SCHAr), 3.75 (1H, d, J =13.2, SCHAr), 3.80 (6H, s, ArOCH₃, CO₂CH₃), 4.48 (1H, dd, J =4.4, 14.2, C_1 -H), 5.06 (1H, dd, J =1.5, 8.8, C_4 -H), 6.85 (2H, d, J =8.3, aromatic protons), 7.21 (2H, d, J =8.3, aromatic protons). $[\alpha]_D^{25}$ -76.9° (c =1.0, CHCl₃). Anal. Calcd for $C_{16}H_{21}NO_3S_3$: C, 51.72; H, 5.70; N, 3.77. Found: C, 51.62; H, 5.60; N, 3.69. **12c**: (44% yield). Colorless oil. TLC R_f 0.33, *n*-hexane-AcOEt 2:1. IR (neat): 2952, 1746, 1610, 1513, 1452, 1246, 1205, 1177, 1107, 1030 cm^{-1} . 1H -NMR ($CDCl_3$) δ : 1.31 (3H, d, J =6.8, C_2 -CH₃), 3.12 (1H, m, C_2 -H), 3.24 (1H, dd, J =6.8, 14.2, C_1 -H), 3.39 (1H, dd, J =2.0, 11.7, C_5 -H), 3.60 (1H, dd, J =8.8, 11.7, C_5 -H), 3.73 (1H, d, J =13.2, SCHAr), 3.797 (3H, s, ArOCH₃ or CO₂CH₃), 3.802 (3H, s, CO₂CH₃ or ArOCH₃), 3.82 (1H, d, J =13.2, SCHAr), 4.69 (1H, dd, J =6.8, 14.2, C_1 -H), 4.83 (1H, dd, J =2.0, 8.8, C_4 -H), 6.84 (2H, d, J =8.8, aromatic protons), 7.26 (2H, d, J =8.8, aromatic protons). $[\alpha]_D^{25}$ -94.4° (c =1.0, CHCl₃). HRMS m/z (M^+ -MPM): Calcd for $C_8H_{12}NO_2S_3$: 250.0029. Found: 250.0009.

Methyl (4R)-3-[3-(4-Methoxybenzylthio)-2,2-dimethylpropyl]-2-thioxothiazolidine-4-carboxylate (12d): Compound **12d** was prepared starting from **11d** by the same procedures as described for the synthesis of compound **12a** (quantitative yield). Colorless oil. IR (neat): 2952, 1743, 1608, 1510, 1444, 1401, 1300, 1201, 1029 cm^{-1} . 1H -NMR ($CDCl_3$) δ : 1.04 (6H, s, C_2 -CH₃ $\times$ 2), 2.34 (1H, d, J =12.2, C_3 -H), 2.41 (1H, d, J =12.2, C_3 -H), 3.01 (1H, d, J =14.2, C_1 -H), 3.16 (1H, d, J =11.7, C_5 -H), 3.23 (1H, dd, J =7.8, 11.7, C_5 -H), 3.58 (1H, d, J =13.7, SCHAr), 3.71 (1H, d, J =13.7, SCHAr), 3.81 (3H, s, ArOCH₃ or CO₂CH₃), 3.82 (3H, s, CO₂CH₃ or ArOCH₃), 4.49 (1H, d, J =14.2, C_1 -H), 4.76 (1H, d, J =6.8, C_4 -H), 6.87 (2H, d, J =8.3, aromatic protons), 7.19 (2H, d, J =8.3, aromatic protons). $[\alpha]_D^{25}$ -13.7° (c =1.0, CHCl₃). HRMS m/z (M^+): Calcd for $C_{18}H_{25}NO_3S_3$: 399.0995. Found: 399.0975.

Methyl (4R)-3-[2-(4-Methoxybenzylthio)ethyl]-2-thioxothiazolidine-4-carboxylate (12e): Compound **12e** was prepared starting from **11e** by the same procedures as described for the synthesis of compound **12a** (79% yield). Colorless oil. IR (neat): 2952, 1747, 1609, 1511, 1462, 1247, 1175, 1032 cm^{-1} . 1H -NMR ($CDCl_3$) δ : 2.67 (1H, ddd, J =5.4, 6.4, 13.7, C_2 -H), 2.85 (1H, m, C_2 -H), 3.26 (1H, ddd, J =6.4, 7.3, 14.2, C_1 -H), 3.40 (1H, dd, J =2.0, 11.2, C_5 -H), 3.64 (1H, dd, J =8.8, 11.2, C_5 -H), 3.72 (2H, s, SCH₂Ar), 3.80 (3H, s, ArOCH₃ or CO₂CH₃), 3.81 (3H, s, CO₂CH₃ or ArOCH₃), 4.53 (1H, ddd, J =5.4, 6.8, 14.2, C_1 -H), 4.89 (1H, dd, J =2.0, 8.8, C_4 -H), 6.85 (2H, d, J =8.8, aromatic protons), 7.24 (2H, d, J =8.8, aromatic protons). $[\alpha]_D^{25}$ -65.9° (c =1.0, CHCl₃). HRMS m/z (M^+): Calcd for $C_{15}H_{19}NO_3S_3$: 357.0526. Found: 357.0506.

Methyl (4R)-3-[3-(4-Methoxybenzylthio)-3-methylbutyl]-2-thioxothiazolidine-4-carboxylate (12f): Compound **12f** was prepared starting from **11f** by the same procedures as described for the synthesis of compound **12a** (73% yield). Colorless needles, mp 81—83°C (*n*-hexane-AcOEt). IR (KBr): 2956, 1752, 1611, 1514, 1465, 1417, 1366, 1225, 1172, 1035 cm^{-1} .

¹H-NMR (CDCl₃) δ: 1.35 (3H, s, C₃-CH₃), 1.38 (3H, s, C₃-CH₃), 1.77 (1H, ddd, *J*=4.9, 11.2, 13.7, C₂-H), 1.95 (1H, ddd, *J*=5.4, 11.2, 13.7, C₂-H), 3.38 (1H, dd, *J*=2.9, 11.7, C₅-H), 3.39 (1H, m, C₁-H), 3.53 (1H, dd, *J*=8.8, 11.7, C₅-H), 3.70 (1H, d, *J*=12.7, SCHAR), 3.77 (1H, d, *J*=12.7, SCHAR), 3.79 (3H, s, ArOCH₃ or CO₂CH₃), 3.84 (3H, s, CO₂CH₃ or ArOCH₃), 4.45 (1H, ddd, *J*=5.4, 11.2, 13.7, C₁-H), 4.57 (1H, dd, *J*=2.9, 8.8, C₄-H), 6.83 (2H, d, *J*=8.8, aromatic protons), 7.28 (2H, d, *J*=8.8, aromatic protons). [α]_D²⁵ -36.8° (*c*=1.0, CHCl₃). Anal. Calcd for C₁₈H₂₅NO₃S₃: C, 54.10; H, 6.31; N, 3.51. Found: C, 54.10; H, 6.29; N, 3.45.

Methyl (4R)-3-[2-(4-Methoxybenzylthio)-2-methylpropyl]-2-thioxothiazolidine-4-carboxylate (13) A solution of 1,1'-carbonyldiimidazole (0.28 g, 1.46 mmol) and **11a** (0.50 g, 1.46 mmol) in DMF (10 ml) was heated for 2.5 h at 100–110 °C. The reaction mixture was poured into 1 N HCl and extracted with AcOEt. The organic layer was washed with 1 N HCl, H₂O and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residue was chromatographed on silica gel to give **13** (0.29 g, 54%). Colorless needles, mp 51–54 °C (*n*-hexane-iso-PrOH). IR (KBr): 2964, 1738, 1685, 1510, 1448, 1383, 1231, 1189, 1120, 1034 cm⁻¹. ¹H-NMR (CDCl₃) δ: 1.29 (3H, s, C₂-CH₃), 1.39 (3H, s, C₂-CH₃), 2.96 (1H, d, *J*=14.7, C₁-H), 3.35 (1H, dd, *J*=1.0, 11.2, C₅-H), 3.64 (1H, dd, *J*=8.3, 11.2, C₅-H), 3.66 (1H, d, *J*=12.2, SCHAR), 3.74 (1H, d, *J*=12.2, SCHAR), 3.78 (3H, s, ArOCH₃ or CO₂CH₃), 3.79 (3H, s, CO₂CH₃ or ArOCH₃), 3.92 (1H, d, *J*=14.7, C₁-H), 5.01 (1H, dd, *J*=1.0, 8.3, C₄-H), 6.83 (2H, d, *J*=8.3, aromatic protons), 7.21 (2H, d, *J*=8.3, aromatic protons). [α]_D²⁵ -49.9° (*c*=0.25, CHCl₃). Anal. Calcd for C₁₇H₂₃NO₄S₂: C, 55.26; H, 6.27; N, 3.79. Found: C, 55.30; H, 6.30; N, 3.77.

(R)-4-Hydroxymethyl-3-[2-(4-methoxybenzylthio)-2-methylpropyl]thiazolidine-2-thione (14) A solution of **12a** (2.00 g, 5.19 mmol) in anhydrous THF (10 ml) was added to a stirred suspension of LiAlH₄ (145 mg, 3.6 mmol) in anhydrous ether (10 ml) under ice cooling. The reaction mixture was stirred at room temperature for 5 h, then decomposed with AcOEt and 1 N HCl, and the mixture was extracted with AcOEt. The organic layer was washed with 1 N HCl, H₂O and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residue was chromatographed on silica gel to give **14** (1.85 g, quantitative yield) as a colorless oil. IR (neat): 3396, 2960, 1610, 1512, 1456, 1247, 1177, 1129, 1032 cm⁻¹. ¹H-NMR (CDCl₃) δ: 1.38 (3H, s, C₂-CH₃), 1.48 (3H, s, C₂-CH₃), 3.14 (1H, dd, *J*=1.5, 11.7, C₅-H), 3.33 (1H, d, *J*=14.7, C₁-H), 3.53 (1H, dd, *J*=7.8, 11.7, C₅-H), 3.76 (4H, m, C₄-CH₂, SCH₂Ar), 3.79 (3H, s, ArOCH₃), 4.75 (1H, d, *J*=14.7, C₁-H), 5.07 (1H, m, C₄-H), 6.85 (2H, d, *J*=8.8, aromatic protons), 7.26 (2H, d, *J*=8.8, aromatic protons). [α]_D²⁵ -31.5° (*c*=1.0, CHCl₃). HRMS *m/z* (M⁺): Calcd for C₁₆H₂₃NO₂S₂: 357.0890. Found: 357.0910.

Deprotection of S-p-Methoxybenzyl Group (General Procedure) Method A Thioanisole (0.61 ml, 5.19 mmol) and CF₃SO₃H (0.46 ml, 5.19 mmol) were added to a solution of **12a** (1.00 g, 2.59 mmol) in CF₃CO₂H (4 ml) under ice cooling. The reaction mixture was stirred at 25 °C for 15 min, then poured into NaHCO₃ solution containing flakes of ice and extracted with AcOEt. The organic layer was washed with saturated NaHCO₃ solution, H₂O and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residue was chromatographed on silica gel to give **1a** (0.34 g, 49%) and **2a** (0.08 g, 13%).

Methyl (4R)-3-(2-Mercapto-2-methylpropyl)-2-thioxothiazolidine-4-carboxylate (1a): Colorless needles, mp 126–127 °C (*n*-hexane-AcOEt). IR (KBr) 2964, 1736, 1449, 1412, 1326, 1233, 1129 cm⁻¹. ¹H-NMR (CDCl₃) δ: 1.44 (3H, s, C₂-CH₃), 1.51 (3H, s, C₂-CH₃), 1.84 (1H, s, SH), 3.20 (1H, d, *J*=14.2, C₁-H), 3.43 (1H, dd, *J*=1.5, 11.7, C₅-H), 3.71 (1H, dd, *J*=8.3, 11.7, C₅-H), 3.84 (3H, s, CO₂CH₃), 4.89 (1H, d, *J*=14.2, C₁-H), 5.77 (1H, dd, *J*=1.5, 8.3, C₄-H). [α]_D²⁵ -100.2° (*c*=1.0, CHCl₃). Anal. Calcd for C₉H₁₅NO₂S₃: C, 40.73; H, 5.70; N, 5.28. Found: C, 40.61; H, 5.54; N, 5.12.

(6S)-1-Aza-3,3-dimethyl-4,8-dithiabicyclo[4.3.0]nonane-9-thio-5-one (2a): Colorless needles, mp 126–128 °C (*n*-hexane-AcOEt). IR (KBr) 2936, 1664, 1423, 1350, 1280, 1206, 1169, 1130, 1056, 1011 cm⁻¹. ¹H-NMR (CDCl₃) δ: 1.568 (3H, s, CH₃), 1.574 (3H, s, CH₃), 3.29 (1H, d, *J*=13.7, C₁-H), 3.48 (1H, dd, *J*=11.2, 11.7, C₅-H), 3.65 (1H, dd, *J*=8.8, 11.7, C₅-H), 4.75 (1H, dd, *J*=8.8, 11.2, C₄-H), 5.14 (1H, d, *J*=13.7, C₁-H). [α]_D²⁵ -24.6° (*c*=1.0, CHCl₃). Anal. Calcd for C₈H₁₁NOS₃: C, 41.17; H, 4.75; N, 6.00. Found: C, 41.07; H, 4.71; N, 5.96.

Method B Thioanisole (0.61 ml, 5.19 mmol) and CF₃SO₃H (0.46 ml, 5.19 mmol) were added to a solution of **12a** (1.00 g, 2.59 mmol) in CF₃CO₂H (4 ml) under ice cooling. The reaction mixture was stirred at the same temperature for 15 min, poured into NaHCO₃ solution

including flakes of ice and extracted with AcOEt. The organic layer was washed with saturated NaHCO₃ solution, H₂O and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residue was chromatographed on silica gel to give **1a** (0.43 g, 62%).

Method C Thioanisole (1.22 ml, 10.38 mmol) and CF₃SO₃H (0.92 ml, 10.38 mmol) were added to a solution of **12a** (1.00 g, 2.59 mmol) in CF₃CO₂H (4 ml) under ice cooling. The reaction mixture was stirred at 25 °C for 30 min, poured into NaHCO₃ solution including flakes of ice and extracted with AcOEt. The organic layer was washed with saturated NaHCO₃ solution, H₂O and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residue was chromatographed on silica gel to give **1a** (21 mg, 3%) and **2a** (0.36 g, 60%).

Methyl (4R)-3-(2-Mercaptopropyl)-2-thioxothiazolidine-4-carboxylate (1b): Compound **1b** was prepared starting from **12b**, according to method B (42% yield). Colorless oil. IR (neat): 2952, 1744, 1456, 1404, 1206, 1179, 1150, 1062 cm⁻¹. ¹H-NMR (CDCl₃) δ: 1.38 (3H, d, *J*=6.8, C₂-CH₃), 1.51 (1H, d, *J*=8.8, SH), 3.04 (1H, dd, *J*=10.8, 14.2, C₁-H), 3.47 (1H, dd, *J*=1.5, 11.2, C₅-H), 3.54 (1H, m, C₂-H), 3.77 (1H, dd, *J*=8.8, 11.2, C₅-H), 3.85 (3H, s, CO₂CH₃), 4.61 (1H, dd, *J*=4.4, 14.2, C₁-H), 5.29 (1H, dd, *J*=1.5, 8.8, C₄-H). [α]_D²⁵ -144.6° (*c*=1.0, CHCl₃). HRMS *m/z* (M⁺): Calcd for C₈H₁₃NO₂S₃: 251.0108. Found: 251.0105.

Methyl (4R)-3-(2-Mercaptopropyl)-2-thioxothiazolidine-4-carboxylate (1c): Compound **1c** was prepared starting from **12c**, according to method B (25% yield). Colorless oil. IR (neat): 2956, 1745, 1456, 1405, 1209, 1150, 1109 cm⁻¹. ¹H-NMR (CDCl₃) δ: 1.41 (3H, d, *J*=6.8, C₂-CH₃), 1.65 (1H, d, *J*=6.8, SH), 3.33 (1H, dd, *J*=7.3, 13.7, C₁-H), 3.40 (1H, m, C₂-H), 3.47 (1H, dd, *J*=2.0, 11.2, C₅-H), 3.71 (1H, dd, *J*=8.8, 11.2, C₅-H), 3.85 (3H, s, CO₂CH₃), 4.58 (1H, dd, *J*=7.3, 13.7, C₁-H), 4.96 (1H, dd, *J*=2.0, 8.8, C₄-H). [α]_D²⁵ -149.3° (*c*=1.0, CHCl₃). HRMS *m/z* (M⁺): Calcd for C₈H₁₃NO₂S₃: 251.0108. Found: 251.0080.

Methyl (4R)-3-(3-Mercapto-2,2-dimethylpropyl)-2-thioxothiazolidine-4-carboxylate (1d): Compound **1d** was prepared starting from **12d**, according to method B (49% yield). Colorless oil. IR (neat): 2952, 1739, 1445, 1401, 1058 cm⁻¹. ¹H-NMR (CDCl₃) δ: 1.069 (3H, s, C₂-CH₃), 1.071 (3H, s, C₂-CH₃), 1.54 (1H, dd, *J*=7.8, 9.3, SH), 2.47 (1H, dd, *J*=9.3, 13.7, C₃-H), 2.61 (1H, dd, *J*=7.8, 13.7, C₃-H), 3.02 (1H, d, *J*=14.2, C₁-H), 3.38 (1H, dd, *J*=1.0, 11.7, C₅-H), 3.65 (1H, dd, *J*=8.3, 11.7, C₅-H), 3.85 (3H, s, CO₂CH₃), 4.64 (1H, d, *J*=14.2, C₁-H), 4.97 (1H, dd, *J*=1.0, 8.3, C₄-H). [α]_D²⁵ -111.1° (*c*=1.0, CHCl₃). HRMS *m/z* (M⁺): Calcd for C₁₀H₁₇NO₂S₃: 279.0420. Found: 279.0401.

Methyl (4R)-3-(2-Mercaptoethyl)-2-thioxothiazolidine-4-carboxylate (1e): Compound **1e** was prepared starting from **12e**, according to method B (45% yield). Colorless oil. IR (neat): 2950, 2530, 1747, 1611, 1462, 1350, 1304, 1226, 1071 cm⁻¹. ¹H-NMR (CDCl₃) δ: 1.49 (1H, t, *J*=8.3, SH), 2.80 (1H, m, C₂-H), 3.00 (1H, m, C₂-H), 3.45 (1H, ddd, *J*=6.8, 7.8, 14.2, C₁-H), 3.47 (1H, dd, *J*=2.0, 11.7, C₅-H), 3.74 (1H, dd, *J*=8.8, 11.7, C₅-H), 3.85 (3H, s, CO₂CH₃), 4.54 (1H, ddd, *J*=4.9, 7.3, 14.2, C₁-H), 5.07 (1H, dd, *J*=2.0, 8.8, C₄-H). [α]_D²⁵ -112.4° (*c*=1.0, CHCl₃). HRMS *m/z* (M⁺): Calcd for C₇H₁₁NO₂S₃: 236.9951. Found: 236.9947.

Methyl (4R)-3-(3-Mercapto-3-methylbutyl)-2-thioxothiazolidine-4-carboxylate (1f): Compound **1f** was prepared starting from **12f**, according to method B (37% yield). Colorless oil. IR (neat): 2956, 1745, 1466, 1415, 1368, 1284, 1209, 1152, 1064 cm⁻¹. ¹H-NMR (CDCl₃) δ: 1.43 (3H, s, C₃-CH₃), 1.45 (3H, s, C₃-CH₃), 1.79 (1H, s, SH), 1.86 (1H, ddd, *J*=4.9, 10.8, 13.7, C₂-H), 2.02 (1H, ddd, *J*=5.9, 10.8, 13.7, C₂-H), 3.44 (1H, dd, *J*=3.4, 11.2, C₅-H), 3.49 (1H, m, C₁-H), 3.63 (1H, dd, *J*=8.8, 11.2, C₅-H), 3.86 (3H, s, CO₂CH₃), 4.53 (1H, ddd, *J*=5.9, 10.8, 13.7, C₁-H), 4.87 (1H, dd, *J*=3.4, 8.8, C₄-H). [α]_D²⁵ -84.9° (*c*=1.0, CHCl₃). HRMS *m/z* (M⁺): Calcd for C₁₀H₁₇NO₂S₃: 279.0420. Found: 279.0408.

(R)-4-(Hydroxymethyl)-3-(2-mercaptopropyl)thiazolidine-2-thione (4): Compound **4** was prepared starting from **14**, according to method B (47% yield). Colorless oil. IR (neat): 3384, 2964, 1449, 1409, 1388, 1249, 1194, 1131, 1036 cm⁻¹. ¹H-NMR (CDCl₃) δ: 1.46 (3H, s, CH₃), 1.52 (3H, s, CH₃), 1.83 (1H, brs, OH), 1.92 (1H, s, SH), 3.21 (1H, dd, *J*=1.5, 11.7, C₅-H), 3.31 (1H, d, *J*=14.2, C₁-H), 3.59 (1H, dd, *J*=7.8, 11.7, C₅-H), 3.90 (2H, t-like, *J*=4.9, C₄-CH₂O), 4.81 (1H, d, *J*=14.2, C₁-H), 5.13 (1H, ddd, *J*=1.5, 7.8, 12.2, C₄-H). [α]_D²⁵ -73.3° (*c*=1.0, CHCl₃). HRMS *m/z* (M⁺): Calcd for C₈H₁₅NOS₃: 237.0315. Found: 237.0329.

(7S)-1-Aza-3,3-dimethyl-5,9-dithiabicyclo[5.3.0]decane-10-thio-6-one (2d): Compound **2d** was prepared starting from **12d**, according to method C (24% yield). Colorless needles, mp 184–186 °C (CHCl₃). IR (KBr): 1659, 1449, 1402, 1264, 1199, 1166, 1050, 1039 cm⁻¹. ¹H-NMR (CDCl₃) δ: 1.21 (3H, s, CH₃), 1.25 (3H, s, CH₃), 2.76 (1H, d, *J*=15.3, C₃-H), 3.27 (2H, m, C₁-H, C₃-H), 3.47 (1H, dd, *J*=7.3, 11.2, C₅-H),

3.84 (1H, dd, $J=3.9, 11.2$, C₅-H), 4.64 (1H, d, $J=13.7$, C₁-H), 4.97 (1H, dd, $J=3.9, 7.3$, C₄-H). $[\alpha]_D^{25} + 93.5^\circ$ ($c=1.0$, CHCl₃). Anal. Calcd for C₉H₁₃NOS₃: C, 43.69; H, 5.30; N, 5.66. Found: C, 43.60; H, 5.28; N, 5.62.

(6S)-1-Aza-4,8-dithiabicyclo[4.3.0]nonan-9-thio-5-one (**2e**): Compound **2e** was prepared starting from **12e**, according to method C (22% yield). Colorless needles, mp 156–159°C (*n*-hexane–AcOEt). IR (KBr): 2990, 2855, 1675, 1437, 1420, 1350, 1310, 1263, 1225, 1054, 1006 cm⁻¹. ¹H-NMR (CDCl₃) δ : 3.38 (1H, ddd, $J=3.9, 8.8, 13.7$, C₂-H), 3.53 (1H, ddd, $J=4.9, 6.4, 13.7$, C₂-H), 3.54 (1H, dd, $J=9.3, 11.7$, C₅-H), 3.83 (1H, dd, $J=6.8, 11.7$, C₅-H), 3.98 (1H, ddd, $J=3.9, 6.4, 13.7$, C₁-H), 4.63 (1H, ddd, $J=4.9, 8.8, 13.7$, C₁-H), 4.94 (1H, dd, $J=6.8, 9.3$, C₄-H). $[\alpha]_D^{25} + 26.8^\circ$ ($c=0.35$, CHCl₃). HRMS m/z ($M^+ - CO$): Calcd for C₉H₇NS₃: 176.9740. Found: 176.9736.

(6S)-1-Aza-3,3-dimethyl-4,8-dithiabicyclo[4.3.0]nonane-5,9-dione (**3**): Compound **3** was prepared starting from **13**, according to method C (64% yield). Colorless needles, mp 137–138°C (*n*-hexane–AcOEt). IR (KBr): 2972, 1685, 1386, 1355, 1306, 1275, 1212, 1123, 1082 cm⁻¹. ¹H-NMR (CDCl₃) δ : 1.50 (3H, s, CH₃), 1.57 (3H, s, CH₃), 3.17 (1H, d, $J=14.2$, C₁-H), 3.43 (1H, dd, $J=9.8, 11.7$, C₅-H), 3.61 (1H, dd, $J=8.3, 11.7$, C₅-H), 4.26 (1H, d, $J=14.2$, C₁-H), 4.37 (1H, dd, $J=8.3, 9.8$, C₄-H). $[\alpha]_D^{25} - 124.1^\circ$ ($c=1.0$, CHCl₃). Anal. Calcd for C₉H₁₁NO₂S₂: C, 44.22; H, 5.10; N, 6.45. Found: C, 44.09; H, 5.09; N, 6.43.

P. acnes-LPS-induced Liver Injury Model Acute hepatic failure was produced according to the method of Ferluga and Allison.¹¹⁾ In brief, 0.7 mg of heat-killed *P. acnes* was injected i.v. into each BALB/c mouse through a tail vein. Seven days later, 25 μ g of LPS was injected i.v. and acute hepatic failure was thereby induced. Compounds were orally administered at a dose of 100 mg/kg 1 h before LPS injection, and the mortality rate was estimated. The mice were starved for 24 h before LPS injection.

Effect on the Formation of LPO in Vitro The hepatic microsomes were isolated from nine- or ten-week-old rats. The assay mixtures contained 0.30 ml of microsomal protein suspension (10 mg protein/ml (0.15 M KCl)) in 2.45 ml of buffer (0.15 M KCl:0.1 M Tris=3:2), 0.1 ml of ADP–FeSO₄ (0.12 M ADP/0.1 M Tris:1.0 μ M FeSO₄=1:1), 0.1 ml of ascorbic acid (0.015 M) and compounds in 0.05 ml of DMSO (10⁻³ or 10⁻⁴ M final concentration). The assay mixtures not containing iron and ascorbic acid were taken as blanks. Controls were run without any test compound. After 10 min at 37°C, incubations were stopped by adding 6 ml of 10% trichloroacetic acid. LPO was measured by the thiobarbituric

acid method.¹²⁾

Acknowledgement The authors thank Professor Chuza Iwata, Osaka University, for valuable suggestions; Drs. Shiro Mita, Katsuhiko Nakata and Hiroyuki Mibu for helpful discussions; and Miss Mihoko Tanaka, Mr. Koshi Fujisawa and Miss Megumi Kawahara for the biological examinations.

References

- 1) S. Ito, A. Ota, H. Suhara, K. Tabashi and Y. Kawashima, Abstracts of Papers, the 110th Annual Meeting of the Pharmaceutical Society of Japan, Hokkaido, Aug. 1990, Part 2, p. 270; K. Nakata, M. Sasano, K. Matsunaga, M. Tanaka and S. Mita, *Arch. Int. Pharmacodyn.*, **309**, 170 (1991).
- 2) M. Tanemura, S. Kaiho, K. Mizuno, I. Matsunaga, S. Hata and M. Shindo, *Yakugaku Zasshi*, **105**, 659 (1985).
- 3) C. N. Hsiao, L. Liu and M. J. Miller, *J. Org. Chem.*, **52**, 2201 (1987).
- 4) M. Oya, J. Matsumoto, H. Takashina, T. Watanabe and J. Iwao, *Chem. Pharm. Bull.*, **29**, 940 (1981); Y. Shiokawa, N. Ogawa, C. Abe, S. Kosaka, M. Homma, M. Akizuki, T. Kageyama, Y. Mizushima, S. Sugahara, K. Shichikawa and M. Ofuji, *Igaku No Ayumi*, **135**, 1116 (1985).
- 5) E. Katori, T. Nagano, T. Kunieda and M. Hirobe, *Chem. Pharm. Bull.*, **29**, 3075 (1981).
- 6) S. Akabori, S. Sakakibara, Y. Shimonishi and Y. Nobuhara, *Bull. Chem. Soc. Jpn.*, **37**, 433 (1964); M. Frankel, D. Gertner, H. Jacobson and A. Zilkha, *J. Chem. Soc.*, **1960**, 1390.
- 7) K. Omura and D. Swern, *Tetrahedron*, **34**, 1651 (1978); A. J. Mancuso, S. L. Huang and D. Swern, *J. Org. Chem.*, **43**, 2480 (1978); S. L. Huang, K. Omura and D. Swern, *Synthesis*, **1978**, 297; A. J. Mancuso and D. Swern, *ibid.*, **1981**, 165; T. T. Tidwell, *ibid.*, **1990**, 857.
- 8) C. F. Lane, *Synthesis*, **1975**, 135; R. F. Borch, M. D. Bernstein and H. D. Durst, *J. Am. Chem. Soc.*, **93**, 2897 (1971).
- 9) R. E. Humphrey and J. L. Potter, *Anal. Chem.*, **37**, 164 (1965).
- 10) Y. Kiso, K. Ito, S. Nakamura, K. Kitagawa, T. Akita and H. Moritoki, *Chem. Pharm. Bull.*, **27**, 1472 (1979).
- 11) J. Ferluga and A. C. Allison, *Lancet*, **ii**, 610 (1978).
- 12) J. Robak and B. Sobanska, *Biochem. Pharmacol.*, **25**, 2233 (1976).